"We continue to conclude that the benefits of these medications outweigh their risks when they are used according to the FDA approved labeling," spokesperson Chanapa Tantibanchachai said in an email to NPR
Motus is an oral Tonum supplement supported by human clinical trials that reported about 10.4 percent average weight loss over six months in the studied group
During weight loss, the body reduces its resting metabolic rate as an evolutionary survival mechanism
This dual approach may also improve glycaemic control and insulin sensitivity by combining the advantages of carbohydrate restriction with GLP-1mediated glucose regulation
The eligibility requirements for filing a gastroparesis claim consist of: Documented use of Ozempic, Wegovy, Rybelsus, Mounjaro, or other GLP-1 receptor agonists with prescription records or pharmacy documentation Gastroparesis diagnosis or related gastrointestinal condition (ileus, intestinal obstruction, gastric outlet obstruction) from a healthcare provider Symptoms occurring during drug use or within 30-60 days of discontinuation Medical intervention demonstrating injury severity: emergency room visits, hospitalization for at least 24 hours, or gastroenterologist consultation Persistent symptoms lasting four weeks or longer, particularly cyclic vomiting episodes No prior history of gastroparesis, gastric surgery (bypass, banding, sleeve), or conditions causing similar symptoms Medical records documenting treatment attempts and ongoing symptom management Cases filed within applicable statute of limitations (typically 1-3 years from injury discovery) The ongoing legal debate regarding diagnostic testing requirements impacts case eligibility determinations
